REFERENCES
- Mayumi T, Takada T, Kawarada Y, Results of the Tokyo Consensus meeting Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):114–121.
- Brook I. Microbiology and management of abdominal infections. Dig Dis Sci. 2008;53(10):2585–2591.
- Paumgartner G. Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J Gastroenterol. 2006;12(28):4445–4451.
- Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339(17):1217–1227.
- Leung JW, Chan RC, Cheung SW, The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime. J Antimicrob Chemother. 1990;25(3):399–406.
- Brook I. Aerobic and anaerobic microbiology of biliary tract disease. J Clin Microbiol. 1989;27(10):2373–2375.
- Westphal JF, Brogard JM, Caro-Sampara F, Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother. 1997;41(8):1636–1640.
- Elaldi N, Soydan S, Turan M, Effect of bile duct obstruction on the biliary secretion of meropenem in rats. Chir Gastroenterol. 2005;21:280–284.
- Wright WE, Line VD. Biliary excretion of cephalosporins in rats: influence of molecular weight. Antimicrob Agents Chemother. 1980;17(5):842–846.
- Joseph SS, John EM, John SB, Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. IDSA guidelines. Clin Infect Dis. 2010;50:133–164.
- Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10.
- Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect. 2005;11(Suppl. 6):10–17.
- Kaya O, Ozdemir F, Atli M, The effects of ciprofloxacin and ursodeoxycholic acid on bacterial translocation in obstructive jaundice. Turk J Gastroenterol. 2009;20(3):186–191.
- Akyürek N, Salman B, Irkörücü O, The effect of platelet activating factor antagonist BN 52021 on bacterial translocation and ICAM-I expression in experimental obstructive jaundice. J Invest Surg. 2005;18(5):247–256.
- Gurleyik E, Coskun O, Ustundag N, Prostaglandin E1 maintains structural integrity of intestinal mucosa and prevents bacterial translocation during experimental obstructive jaundice. J Invest Surg. 2006;19(5):283–289.
- Lipsett PA, Pitt HA. Acute cholangitis. Surg Clin North Am. 1990;70(6):1297–1312.
- Yalcın AN. Antibiyotik tedavisindeki basarısızlıklarda konağa ve antibiyotiğe ait faktörler (The factors that atributable to antibiotic and patient for antibiotic treatment inefectivity). Aknem Dergisi. 2001;15(3):293–297.
- Westphal JF, Brogard JM. Biliary tract infections: a guide to drug treatment. Drugs. 1999;57(1):81–91.
- Nemutlu E, Kir S, Katlan D, Simultaneous multiresponse optimization of an HPLC method to separate seven cephalosporins in plasma and amniotic fluid: application to validation and quantification of cefepime, cefixime and cefoperazone. Talanta. 2009;80(1):117–126.
- Williams JD, Naber KG, Bryskier A, Classification of oral cephalosporins: a matter for debate. Int J Antimicrob Agents. 2001;17(6):443–450.
- Rippin SJ, Hagenbuch B, Meier PJ, Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology. 2001;33(4):776–782.
- Kohner PC, Robberts FJ, Cockerill FR III, Cephalosporin MIC distribution of extended-spectrum-β-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol. 2009;47(8):2419–2425.